Author

Victoria Ford

Observed names: V. Ford, Victoria A Ford

Institutions: Torbay and South Devon NHS Foundation Trust, Royal Devon University Healthcare NHS Foundation Trust

Observed institutions: Royal Devon & Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital, Torbay and South Devon NHS Foundation Trust, Royal Devon University Healthcare NHS Foundation Trust

ORCID: 0000-0001-5837-4089

Observed ORCID: 0000-0001-5837-4089

OpenAlex ID: A5041959821

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

2022 · Nicholas D James, Fiona C Ingleby, et al. · JNCI Cancer Spectrum · 28

1463P Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review

2022 · A. Challapalli, G. Ratnayake, et al. · Annals of Oncology · 2

Introduction of adjuvant immunotherapy into the renal surgery pathway: Are eligible patients receiving treatment in time in the UK NHS setting?

2026 · Melissa-Rose Bennett, Grace Liversedge, et al. · Journal of Clinical Urology

Transforming kidney cancer treatment through AI-enabled functional precision medicine: The PEAR-TREE2 trial.

2025 · Matthew Williams, Ekaterini Boleti, et al. · Journal of Clinical Oncology

First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine?

2025 · Ben Crosby, Ricky Dylan Frazer, et al. · Journal of Clinical Oncology

Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.

2023 · John McGrane, Ricky Frazer, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 30

H-index: 2

I10-index: 1